New York, Jan 24, 2026, 17:24 EST — Market closed.
- Amgen shares slipped 0.7% to $344.75 on Friday, ending a six-day winning run.
- After hitting a new 52-week high on Thursday, the stock wrapped up the week with gains.
- Attention shifts to the Fed’s decision next week, along with Amgen’s Feb. 3 earnings call for updates on guidance and its pipeline.
Amgen Inc. shares dipped 0.7% on Friday, closing at $344.75. This halted a six-day winning streak, though the stock still stands roughly 4% higher than it was a week ago. 1
The stock hit $349.98 on Thursday, pressing against the upper boundary of its 52-week range, which spans from $261.43 to $349.98, based on price data. 2
Next week’s jam-packed schedule could quickly shift risk appetite. Investors are bracing for a Federal Reserve decision on Wednesday, plus a flood of quarterly earnings from major U.S. companies, according to a Reuters Week Ahead column. “At the end of the day, earnings are the driver,” said Chris Galipeau, senior market strategist at Franklin Templeton, in comments to Reuters. 3
Wall Street wrapped up a choppy week as the Dow slipped while the S&P 500 barely moved. Intel’s shares dropped after it warned of a dimmer outlook, and ongoing geopolitical tensions rattled investors, Reuters reported on Friday. 4
Amgen now faces the test of whether its stock rally can hold through earnings season. Investors are zeroing in on MariTide, its obesity drug candidate, pitched as a less frequent injection alternative to the weekly shots from Eli Lilly and Novo Nordisk. Amgen’s R&D head Jay Bradner told Reuters the company is “unambiguously in the lead” for monthly-or-less dosing. BMO analyst Evan Seigerman highlighted the maintenance use case as the key to the drug’s valuation. 5
In November, Amgen’s latest quarterly results surpassed expectations, prompting the company to raise its full-year earnings forecast. The boost came largely from higher sales of drugs like the cholesterol medication Repatha, Reuters reported. 6
The obesity program still poses a risk to sentiment. Previous MariTide studies reported significant weight loss but also gastrointestinal side effects. Investors are awaiting more detailed updates on tolerability and dosing from longer trials. 7
Income-focused investors are eyeing the dividend schedule closely. Amgen announced its board has approved a quarterly dividend of $2.52 per share. Shareholders on record by Feb. 13 will get the payment on March 6. 8
Amgen’s next major company event is just around the corner. The biotech firm has scheduled its fourth-quarter 2025 earnings call for Tuesday, Feb. 3, at 1:30 p.m. PST, according to its investor relations calendar. 9
